LFST · LifeStance Health Group, Inc.

The thesis

LifeStance Health's third-quarter profit guidance sits below what the company already earned in the second quarter, so the company can meet it without any further improvement. The shares still trade under the $12.35 price of September's shareholder offering. The third-quarter report, estimated for about 5 November 2026 and not yet scheduled by the company, settles the case. It tests the guidance issued on 6 August 2026: quarterly revenue of $420–440 million and adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA) of $49–59 million. It also tests whether full-year adjusted EBITDA of $215–235 million holds or rises.

Little has changed since the prior update. The shares closed at $12.06 on 8 October 2026, below the $12.22 close that followed KeyBanc's target raise on 5 October 2026. The company has issued no new results or guidance since 6 August 2026, and its investor-relations site lists no third-quarter report date yet. The 7 October 2026 Benzinga item was a republished transcript of the second-quarter call, with nothing new in it.

The narrative is maturing: the margin story has been public since the 6 August 2026 report, and KeyBanc's 5 October 2026 raise repeated the $15 target that Canaccord Genuity and Barclays set in September.

Bullish and bearish views on LifeStance Health Group, Inc.

The bull case on LifeStance Health Group, Inc. (LFST), in brief: Second-quarter profit beat guidance. The bear case: Selling stockholders keep adding supply.

Bull case

• Second-quarter profit beat guidance. LifeStance reported adjusted EBITDA of $66.0 million, or 15.2% of revenue, on 6 August 2026, against guidance of $50–60 million. Net income was $23.6 million, against a $3.8 million loss a year earlier, per the company's 8-K exhibit.
• Revenue growth outran the estimate. Second-quarter revenue was $435.35 million, up 26.1% from a year earlier and above the $414.58 million analyst estimate, per MarketBeat. The clinician count reached 8,542, up 11%, per the 6 August 2026 release.
• The third-quarter guide is set low. The $49–59 million adjusted-EBITDA range sits below the $66.0 million just reported. Center Margin, a company measure that excludes corporate overhead, is guided to $140–152 million against $153.0 million in the second quarter.
• Cash flow matched the earnings. Second-quarter operating cash flow was $99.9 million and free cash flow $87.9 million, per the 6 August 2026 release. Cash was $225.9 million against net long-term debt of $259.0 million, and the board authorized a $100 million repurchase.
• Analyst targets keep moving up. KeyBanc raised its target from $13 to $15 on 5 October 2026, after identical raises by Canaccord Genuity on 9 September 2026 and Barclays on 10 September 2026. MarketBeat put the consensus target at $13.12 on 5 October 2026, with BTIG's $18 the highest.

Bear case

• Selling stockholders keep adding supply. Existing holders priced 22.25 million shares at $12.35 on 9 September 2026, and the company received no proceeds. MarketBeat counts $146.4 million of insider sales over the three months to 5 October 2026.
• An executive sold into the rally. A Form 4 filed 4 September 2026 shows Chief Technology Officer Vukasin Paunovich sold 42,067 shares on 2 September 2026 at a weighted average of $12.87.
• The offering price still caps the shares. The $12.06 close on 8 October 2026 sits below the $12.35 offering price a month after the sale. The shares closed as low as $11.83 on 2 October 2026.
• The valuation leans on adjusted measures. MarketBeat listed a price-to-earnings ratio of 91.01 on 5 October 2026. GuruFocus put its GF Value estimate at $8.82 on the same date, well under the share price.

Price setup

Adjusted daily closes put LFST at $12.06 on 8 October 2026, 9.9% under its 52-week high of $13.38 and up 10.8% over three months. The 14-day relative strength index, a momentum gauge running from 0 to 100, stood at 36.9, which points to fading short-term buying. MarketBeat listed the 50-day moving average at $12.07 and the 200-day at $9.58 on 5 October 2026, so the shares now sit on the shorter average.

The price range since the offering runs from the $11.83 close on 2 October 2026 to the $12.35 offering price. A close back above $12.35 would show the September supply absorbed. A weekly close below $11.00 would put the shares under the post-offering low and the 50-day average and end the case.

Crowding is visible on the supply side. Insider and selling-stockholder sales of $146.4 million in three months and the 22.25 million-share offering outweigh any sign of retail excess, and the shares are not stretched far above the 50-day average.

Catalysts, next 30 days

• 16 October 2026: Final approval hearing for the tracking-pixel class-action settlement in the U.S. District Court for the District of Arizona. The settlement is about $3 million and does not bear on the margin case.
• ~5 November 2026, est.: Third-quarter 2026 results. MarketBeat lists the date; the company has not announced it. The report tests revenue against $420–440 million, adjusted EBITDA against $49–59 million and full-year guidance of $1.685–1.725 billion in revenue and $215–235 million in adjusted EBITDA.

What would change the view

The case breaks if the second-quarter profit gain fails to carry forward. Third-quarter revenue below $420 million, adjusted EBITDA below $49 million, or any cut to the $215–235 million full-year adjusted-EBITDA guidance would show that. Visit growth falling below clinician growth would undercut it too; in the second quarter visits grew 19% and clinicians 11%.

On price, a weekly close below $11.00 would put the shares under the $11.83 close of 2 October 2026 and the 50-day average. Another underwritten secondary offering before the report would extend the supply problem.

The case strengthens if the report clears the top of the $49–59 million range and the company raises full-year guidance, or if the shares close above the $12.35 offering price.

What it trades with

LFST trades mainly on company events: the 6 August 2026 report, the 9 September 2026 offering and the 5 October 2026 target raise set the recent moves. Its revenue depends on commercial insurers' reimbursement rates, so payer policy changes on outpatient mental-health visits affect it more than the broad market does. KeyBanc's 5 October 2026 note named reimbursement economics as the key growth factor.